Loading...
•
Sep 30
Quantum-Si Q3 2025 Earnings Report
Quantum-Si reported its third quarter 2025 financial results, highlighting revenue of $552,000 and a net loss of $35.7 million. The company also announced successful sequencing on a prototype Proteus unit and progress in its instrument placement program.
Key Takeaways
Quantum-Si reported a revenue of $552,000 for the third quarter of 2025, a decrease from the prior year. The company experienced a net loss of $35.7 million, significantly higher than the previous year, primarily due to one-time charges for legacy litigation settlements and lease termination expenses. Despite the financial losses, Quantum-Si made progress on its Proteus development program and expanded its instrument placement program to academic customers.
Revenue for Q3 2025 was $552,000, a decrease compared to $787,000 in Q3 2024.
Net loss for Q3 2025 was $35.7 million, an increase from $25.3 million in Q3 2024, largely due to $15.4 million in one-time charges.
Adjusted EBITDA for Q3 2025 was negative $20.1 million, an improvement from negative $24.5 million in Q3 2024.
The company successfully demonstrated sequencing on a prototype Proteus system and remains on track for its launch in the second half of 2026.
Quantum-Si
Quantum-Si
Quantum-Si Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService Revenue
CapyFin.com Forward Guidance
Quantum-Si is focused on increasing customer access to its technology through various instrument acquisition options and advancing its Proteus platform development, with a planned launch in the second half of 2026. The company also anticipates launching its version 3 Library Prep Kit before year-end 2025.
Positive Outlook
- Successful sequencing runs on a prototype Proteus system, keeping the development program on track for a H2 2026 launch.
- Early success with the instrument placement program, increasing access for academic customers.
- Recent launch of the version 4 Sequencing Kit.
- Version 3 Library Prep Kit for low input samples remains on track for launch before year-end 2025.
- Cash and cash equivalents and marketable securities of $230.5 million are anticipated to carry operations into the second quarter of 2028.
Challenges Ahead
- The periodic gross margin rate is expected to be variable in the near term.
- The company is working through initial stages of commercialization, which can lead to variability.
- NIH funding uncertainty is a headwind for instrument acquisition.
- Significant net losses continue, although adjusted EBITDA improved.
- The company incurred substantial one-time charges related to legacy litigation and lease termination in the current quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income